Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Interest Expenses (2022 - 2025)

Historic Interest Expenses for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Q3 2025 value amounting to $2.3 million.

  • Tarsus Pharmaceuticals' Interest Expenses fell 723.93% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 3841.56%. This contributed to the annual value of $7.8 million for FY2024, which is 13457.86% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Interest Expenses of $2.3 million as of Q3 2025, which was down 723.93% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Interest Expenses ranged from a high of $2.4 million in Q3 2024 and a low of $316000.0 during Q1 2022
  • For the 4-year period, Tarsus Pharmaceuticals' Interest Expenses averaged around $1.3 million, with its median value being $983000.0 (2024).
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Interest Expenses soared by 18496.5% in 2024, and later plummeted by 723.93% in 2025.
  • Tarsus Pharmaceuticals' Interest Expenses (Quarter) stood at $692000.0 in 2022, then soared by 42.92% to $989000.0 in 2023, then surged by 133.77% to $2.3 million in 2024, then dropped by 1.9% to $2.3 million in 2025.
  • Its Interest Expenses stands at $2.3 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.2 million for Q1 2025.